Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chamomilla tincture mouthwash is a herbal pharmaceutical developed by Mashhad University of Medical Sciences for the treatment of recurrent aphthous stomatitis (RAS). Derived from the fluid extract of *Chamomilla recutita* (German chamomile), its primary active constituents include chamazulene and azulene, along with various flavonoids. The drug exerts its therapeutic effects through anti-inflammatory, analgesic, antibacterial, and antifungal activities. Specifically, chamazulene inhibits leukotriene B4 synthesis and the peroxidation of arachidonic acid in neutrophils, thereby reducing inflammation and pain associated with oral ulcers. Clinical evaluation in a Phase 1 trial demonstrated its efficacy in controlling pain and burning sensations in patients with RAS without significant adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chamomilla tincture.